Clinical Trials

Diseases Treated:

Sickle Cell Disease

Eligibility:

•  18 to 35 years old
• Diagnosed with severe sickle cell disease

Diseases Treated:

Sickle Cell Disease

Eligibility:

• 2–11 years old
• Diagnosed with severe sickle cell disease (SCD)

Diseases Treated:

• Acute myeloid leukemia
• Myelodysplastic syndrome

Eligibility:

• 1–22 years old
• Treatment-related or secondary MDS/AML 

Diseases Treated:

Blood clots (venous thromboembolism)

Eligibility:

This clinical trial is open only to St. Jude patients.

• Newborn to 17 years old (must be younger than 18)
• Diagnosis of blood clot in a vein (venous thromboembolism, also called VTE)
• Requires anticoagulant therapy for at least 90 days
• Received at least 5 days of heparin therapy prior to study

Diseases Treated:

Hemophilia B

Eligibility:

• Male
• At least 18 years old
• Diagnosis of hemophilia B

Diseases Treated:

Neurological Disorders
Sickle Cell Disease
Hemophilia
Inherited Genetic Diseases

Eligibility:

• Non-therapeutic clinical trial
• Interviews conducted remotely
• 18-35-year-olds with rare genetic diseases
• Parents or caregivers of patients under 21 with rare genetic diseases
• Health care workers for gene therapy patients

Diseases Treated:

Hemophilia A

Eligibility:

• Male
• At least 18 years old
• Severe hemophilia A

Diseases Treated:

Aplastic Anemia

Eligibility:

• 21 years old and younger
• Diagnosis of severe aplastic anemia
• No available matched donor

Diseases Treated:

Non-malignant blood diseases (non-therapeutic)

Eligibility:

• Receiving therapy or a consultation for a non-malignant blood disorder
• Biological relatives (with or without a non-malignant blood disorder) who agree to undergo genetic testing

Diseases Treated:

Sickle Cell Disease

Eligibility:

This is a non-therapeutic study for patients at St. Jude Children’s Research Hospital and Methodist Adult Comprehensive Sickle Cell Center.

• Diagnosis of sickle cell disease (SCD)
• 16 to 20 years old
• English is primary language

Diseases Treated:

X-linked Severe Combined Immunodeficiency (SCID-X1)

Eligibility:

• Diagnosis of Severe Combined Immunodeficiency, X-linked (SCID-X1)
• Newborn to 2 years of age
• No prior therapy with allogeneic stem cell transplantation
• No HIV infection

Diseases Treated:

Sickle Cell Disease

Eligibility:

• 25 years old or younger
• Diagnosed with severe sickle cell disease
• Has a suitable HLA-matched sibling donor or single haplotype matched (half matched) family member donor (parents or siblings)

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

• Participant is receiving an allogeneic hematopoietic stem cell transplant at St. Jude Children’s Research Hospital using an unlicensed cord blood unit (CBU).
• The patient has a disorder affecting the hematopoietic system that is either inherited, acquired, or a result from myeloablative treatment.

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

Diseases Treated:

Acute Myelogenous Leukemia

Eligibility:

• 21 years old or younger
• Relapsed/refractory CD123+ AML, B-ALL, T-ALL or blastic plasmacytoid dendritic cell neoplasm
• Has a suitable bone marrow transplant donor for allogeneic bone marrow transplant

Diseases Treated:

• Acute lymphoblastic leukemia
• Acute myeloid leukemia
• Myelodysplasia
• Hodgkin lymphoma
• Non-Hodgkin lymphoma
• Juvenile myelomonocytic leukemia

Eligibility:

• Ages 12–21 years
• Lymphoid or myeloid-based cancer that requires a bone marrow transplant

 

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

• Participant received an integrating retroviral or lentiviral vector based gene transfer or gene marked product at St. Jude Children’s Research Hospital within the past 15 year time period.

Diseases Treated:

• Acute lymphoblastic leukemia
• Acute myeloid leukemia
• Myelodysplasia
• Hodgkin lymphoma
• Non-Hodgkin lymphoma
• Juvenile myelomonocytic leukemia

Eligibility:

For transplant recipient:

• 21 years or younger
• Does not have a suitable sibling donor or volunteer unrelated donor
• Has a suitable single haplotype matched family member donor
• Diagnosed with high risk hematologic malignancy
• No prior allogeneic hematopoietic cell transplant

Diseases Treated:

Aplastic Anemia

Eligibility:

• 21 years old and younger
• Diagnosis of severe aplastic anemia
• No available matched donor

Diseases Treated:

X-linked Severe Combined Immunodeficiency (SCID-X1)

Eligibility:

• Diagnosis of Severe Combined Immunodeficiency, X-linked (SCID-X1)
• Newborn to 2 years of age
• No prior therapy with allogeneic stem cell transplantation
• No HIV infection

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

Donor eligibility includes:

• At least 18 years old
• At least single haplotype matched family member
• HIV negative
• Not pregnant or breastfeeding

Recipient eligibility includes:

• 21 years old or younger*
• Diagnosed with relapsed and/or refractory CD19-positive leukemia
• Cohort A only – Relapsed and/or refractory CD19-positive leukemia AND previously received a hematopoietic cell transplant from the selected CAR-T donor
• Cohort B only: Can not receive autologous CD19-CAR T-cell therapy (per study)
• Detectable medullary leukemia

* Initial 3 participants must be at least 16 years old.

Diseases Treated:

Leukemia and other blood diseases

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

• Participant is receiving an allogeneic hematopoietic stem cell (HSC) transplant at St. Jude Children's Research Hospital using an unlicensed cord blood unit (CBU).
• Participant may be of any age and either gender.
• Participant has a medical disorder affecting the hematopoietic system that is inherited, acquired, or a result from myeloablative treatment.
• Participant is receiving HPC-CORD BLOOD product manufactured by NCBP (at least one, if the graft contains more than one units).

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

Diseases Treated:

• Leukemia
• Lymphoma
• Myeloid sarcoma
• Myelodysplastic syndrome

Eligibility:

• 21 years old and younger
• Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia
  • Myeloid sarcoma
  • Chronic myeloid leukemia (CML)
  • Juvenile myelomonocytic leukemia (JMML)
  • Myelodysplastic syndrome (MDS)
  • Non-Hodgkin lymphoma (NHL)
• Has a family member who is a suitable stem cell donor

Diseases Treated:

Sickle Cell Disease

Eligibility:

• 25 years old or younger
• Diagnosed with severe sickle cell disease
• Has a suitable HLA-matched sibling donor or single haplotype matched (half matched) family member donor (parents or siblings)

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

• Children and young adults up to 21 years old
• Refractory or relapsed CD19+ acute lymphoblastic leukemia (ALL)

 

 

Diseases Treated:

 Low-grade glioma

Eligibility:

• At least 6 years old and younger than 22
• Diagnosis of low-grade glioma

Diseases Treated:

Brain tumors
DIPG

Eligibility:

• Up to 21 years old
• Either B7-H3–positive relapsed or refractory non-brainstem primary CNS tumor or brainstem high-grade neoplasm

Diseases Treated:

Solid tumors, Brain tumors

Eligibility:

• 6 months to 21 years old
• Solid tumor or brain tumor that has progressed or spread
• Failed standard treatment
• RET gene alteration

Diseases Treated:

Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma or high-grade glioma

Eligibility:

• Between 6 months and 18 years old with diagnosis of MSI-H solid tumor OR
• Between 12 years and 18 years old with diagnosis of melanoma OR
• Between 3 and 18 years old with relapsed or refractory classical Hodgkin lymphoma OR
• Between 12 and 18 years old with a diagnosis of Stage IIB, IIC, III, or IV melanoma, who had prior surgery to remove the tumor, but no other treatment (including radiation), no metastatic disease, and who have completely recovered. 
• Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
• Appropriate liver and kidney functions

Diseases Treated:

Recurrent, progressive, or refractory high-grade gliomas

Eligibility:

• Participant has recurrent, progressive or refractory non-brainstem high-grade glioma or diffuse intrinsic pontine glioma (DIPG)
• Participant is 1 to 18 years of age
• Participant has bi-measurable disease on MRI 
• Participant has received prior radiation therapy and/or chemotherapy and has not received myelosuppressive anticancer chemotherapy for at least three (3) weeks

 

Diseases Treated:

High-grade glioma (HGG), ependymoma

Eligibility:

• Between 5 and 21 years old
• Diagnosis of supratentorial high-grade glioma (HGG) or supratentorial ependymoma that is recurrent, progressive or refractory
• Head circumference of at least 44 cm
• Failed standard therapy with no other available treatment options
• Recovered from prior chemotherapy, immunotherapy or radiotherapy
• Willing and able to use the device at least 18 hours a day for at least 23 days and keep head shaved throughout treatment

Diseases Treated:

Medulloblastoma

High-grade glioma (HGG)

Diffuse intrinsic pontine glioma (DIPG)

Eligibility:

• Recurrent, refractory or progressive medulloblastoma, high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG)
• Evidence of genetic activation of the MET pathway (expansion co-hort)
• At least 5 years old and 21 years old or younger

Diseases Treated:

Solid Tumor

Lymphoma

Brain Tumor

Eligibility:

• 12 months to 21 years old with diagnosis of:
  • Relapsed or refractory solid tumor or lymphoma (including CNS tumors) OR
  • Progressive or recurrent DIPG or other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy
• 12 months to 30 years old with diagnosis of relapsed or refractory osteosarcoma

Diseases Treated:

Diffuse Intrinsic Pontine Glioma, Glioma, CNS Tumor, Solid Tumor

Eligibility:

• Diagnosed with one of the following:
  • Recurrent or refractory solid tumor or central nervous system (CNS) tumor
  • Diffuse Intrinsic Pontine Glioma  (DIPG)
  • Newly diagnosed or recurrent high-grade glioma 
• Younger than 18 years old (Phase I) or between 3 and 25 years old (Efficacy Phase)

Diseases Treated:

Craniopharyngioma

Eligibility:

• 21 years old or younger
• Diagnosis of craniopharyngioma

Diseases Treated:

Low-Grade Glioma

Eligibility:

At least 2 years old and younger than 25 years old

Diagnosis of progressive or relapsed low-grade glioma 

Diseases Treated:

Medulloblastoma

Eligibility:

• All patients with newly diagnosed medulloblastoma between birth and 3 years old
• A select group of low-risk patients with newly diagnosed medulloblastoma between 3 and 5 years old
• No previous radiotherapy, chemotherapy, or other treatment for the brain tumor other than corticosteroid therapy and surgery

 

Eligibility Exclusions:

• Other medical disorders, such as serious infections or significant heart, lung, liver, psychiatric, or other organ problems that could make it hard to cope with the trial treatment or would interfere with the study procedure

Diseases Treated:

Medulloblastoma (includes all variants of medulloblastoma and posterior fossa PNET)

Eligibility:

• Diagnosis of newly medulloblastoma
• At least 3 years old and younger than 22 years old (Strata W, S or N) OR
• At least 22 years old and younger than 40 years old AND has SHH medulloblastoma (Stratum S)
• Has not received previous treatment with radiation therapy or chemotherapy
• Must start treatment within 36 days of surgery to remove the tumor

Diseases Treated:

Brain tumor

Eligibility:

This study is open only to patients at St. Jude Children’s Research Hospital.

• Diagnosis of medulloblastoma or other brain tumor
• Between 8 and 12 years old
• At least 2 years after completion of therapy
• Full-time student
• Speaks English

Diseases Treated:

Solid Tumors

Eligibility:

Inclusion criteria include:

• 21 years old or younger
• Relapsed or refractory B7-H3-positive solid tumor

Diseases Treated:

Acute Myelogenous Leukemia

Eligibility:

• 21 years old or younger
• Relapsed/refractory CD123+ AML, B-ALL, T-ALL or blastic plasmacytoid dendritic cell neoplasm
• Has a suitable bone marrow transplant donor for allogeneic bone marrow transplant

Diseases Treated:

Brain tumors
DIPG

Eligibility:

• Up to 21 years old
• Either B7-H3–positive relapsed or refractory non-brainstem primary CNS tumor or brainstem high-grade neoplasm

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

Donor eligibility includes:

• At least 18 years old
• At least single haplotype matched family member
• HIV negative
• Not pregnant or breastfeeding

Recipient eligibility includes:

• 21 years old or younger*
• Diagnosed with relapsed and/or refractory CD19-positive leukemia
• Cohort A only – Relapsed and/or refractory CD19-positive leukemia AND previously received a hematopoietic cell transplant from the selected CAR-T donor
• Cohort B only: Can not receive autologous CD19-CAR T-cell therapy (per study)
• Detectable medullary leukemia

* Initial 3 participants must be at least 16 years old.

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

• Children and young adults up to 21 years old
• Refractory or relapsed CD19+ acute lymphoblastic leukemia (ALL)

 

 

Diseases Treated:

Non-therapeutic

Eligibility:

This is a non-therapeutic clinical trial that is open to St. Jude patients.

• Solid tumor or liquid tumor (cancerous or non-cancerous)

Diseases Treated:

Neurological Disorders
Sickle Cell Disease
Hemophilia
Inherited Genetic Diseases

Eligibility:

• Non-therapeutic clinical trial
• Interviews conducted remotely
• 18-35-year-olds with rare genetic diseases
• Parents or caregivers of patients under 21 with rare genetic diseases
• Health care workers for gene therapy patients

Eligibility:

• Diagnosis of a primary immunodeficiency predisposed to hemophagocytic lymphohistiocytosis
• Meets at least 4 of 8 diagnostic criteria for HLH as defined by the Histiocyte Society and is receiving HLH-directed therapy
• High suspicion of isolated Central Nervous System-HLH and is receiving HLH-directed therapy

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients

Diseases Treated:

None

Eligibility:

This is a non-therapeutic clinical trial that is open only to St. Jude patients.

• Younger than 25 years
• Undergoing cancer therapy at St. Jude Children’s Research Hospital
• Considered to be at high risk of infection

Diseases Treated:

Non-therapeutic clinical trial

Eligibility:

This is a non-therapeutic clinical trial that is open to children and adults with familial cancer and to their eligible family members.

Note: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical genetic testing, please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for the SJFAMILY study, as outlined below, you may enroll regardless of the results of your clinical genetic testing.

In this research study, the definition of “Familial Cancer” is met if any of the following is present:

• An individual with a history of cancer diagnosed under 26 years of age who has at least one first, second or third degree relative with a history of cancer diagnosed under 51 years of age; OR
• An individual who has been diagnosed  with more than one cancer, at least one of which was diagnosed under 26 years of age; OR
• An individual with a clinical or molecular diagnosis of a known cancer predisposition syndrome; OR
• An individual with a congenital cancer that was diagnosed before 6 months of age; OR
• An individual with a rare pediatric cancer or tumor diagnosed before 26 years of age. Examples of rare pediatric tumors include (but are not limited to): carcinoma or precursor carcinoma lesions of any organ or anatomic site and cutaneous malignant cancers. Additional rare pediatric tumors to be included will be defined as any solid malignancy or borderline tumor characterized by an annual incidence of less than two occurrences per million per year (such as ectomesenchymoma). 

Eligible individuals include:

• An individual who meets the definition of “Familial Cancer,” as above
• Blood relatives of the above individual with familial cancer, who are affected or unaffected by cancer

Eligibility:

• Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
• Child has adequate blood, liver and kidney function.
• Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.

Diseases Treated:

Hemophagocytic Lymphohistiocytosis

Eligibility:

• 6 weeks to 22 years old
• Newly diagnosed hemophagocytic lymphohistiocytosis (HLH)
• Relapsed or refractory HLH

Eligibility:

• Diagnosis of a primary immunodeficiency predisposed to hemophagocytic lymphohistiocytosis
• Meets at least 4 of 8 diagnostic criteria for HLH as defined by the Histiocyte Society and is receiving HLH-directed therapy
• High suspicion of isolated Central Nervous System-HLH and is receiving HLH-directed therapy

Diseases Treated:

Langerhans cell histiocytosis

Eligibility:

• Diagnosis of Langerhans cell histiocytosis
• Younger than 18 years old
• Meets inclusion criteria for the respective stratum

 

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

• Participant received an integrating retroviral or lentiviral vector based gene transfer or gene marked product at St. Jude Children’s Research Hospital within the past 15 year time period.

Eligibility:

• Diagnosis of a primary immunodeficiency predisposed to hemophagocytic lymphohistiocytosis
• Meets at least 4 of 8 diagnostic criteria for HLH as defined by the Histiocyte Society and is receiving HLH-directed therapy
• High suspicion of isolated Central Nervous System-HLH and is receiving HLH-directed therapy

Diseases Treated:

X-linked Severe Combined Immunodeficiency (SCID-X1)

Eligibility:

• Diagnosis of Severe Combined Immunodeficiency, X-linked (SCID-X1)
• Newborn to 2 years of age
• No prior therapy with allogeneic stem cell transplantation
• No HIV infection

Diseases Treated:

HIV Infection

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

• The subject has been enrolled on IMPAACT P1025.

Diseases Treated:

HIV/AIDS

Eligibility:

• Participant is HIV-1 infected male or female aged six (6) to less than eight-teen (18) years of age at Baseline.
• Participant is currently on a stable 2-NRTI (TDF containing) regimen that includes a protocol specified 3rd ARV agent for greater than or equal to six (6) consecutive months prior to screening.
• Participant does not have an acquired immunodeficiency syndrome (AIDS) indicator condition with onset within thirty (30) days prior to screening.

Diseases Treated:

Human Immunodeficiency Virus

Eligibility:

• At least 4 weeks old but younger than 18 years old
• Confirmed HIV-1 infection
• Current or past treatment with HIV medications (Children younger than 2 years old may be eligible even if they have not been treated with HIV medications.)

Diseases Treated:

None

Eligibility:

This is a non-therapeutic clinical trial that is open only to St. Jude patients.

• Younger than 25 years
• Undergoing cancer therapy at St. Jude Children’s Research Hospital
• Considered to be at high risk of infection

Eligibility:

• Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
• Child has adequate blood, liver and kidney function.
• Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.

Diseases Treated:

leukemia, solid tumor, brain tumor, lymphoma, carcinoma

Eligibility:

This is a non-therapeutic clinical trial open to patients receiving treatment at a Children’s Oncology Group (COG)-affiliated institution.

• At least 8 years old and younger than 16 years old
• Diagnosed with childhood cancer, in remission
• Completed therapy within the past 12 months
• Performance status corresponding to ECOG scores of 0, 1, 2
• Fewer than 420 minutes of moderate to vigorous physical activity (MVPA) over the last week
• Able to write and read English, Spanish or French (patient and at least one parent/guardian)
• Not pregnant

Diseases Treated:

Acute Myeloid Leukemia (AML)

Eligibility:

• Diagnosed with AML
• Older than 28 days and younger than 22 years
• No prior AML treatment

Diseases Treated:

Acute myeloid leukemia (AML)

Eligibility:

• Diagnosis of relapsed acute myeloid leukemia (AML)
• Ages 29 days old to 21 years old
• Have had AML come back for the first or second time
• May have heart problems that prevent them from taking anthracyclines

Diseases Treated:

Acute Myelogenous Leukemia

Eligibility:

• 21 years old or younger
• Relapsed/refractory CD123+ AML, B-ALL, T-ALL or blastic plasmacytoid dendritic cell neoplasm
• Has a suitable bone marrow transplant donor for allogeneic bone marrow transplant

Diseases Treated:

• Acute lymphoblastic leukemia
• Acute myeloid leukemia
• Myelodysplasia
• Hodgkin lymphoma
• Non-Hodgkin lymphoma
• Juvenile myelomonocytic leukemia

Eligibility:

• Ages 12–21 years
• Lymphoid or myeloid-based cancer that requires a bone marrow transplant

 

Diseases Treated:

Leukemia

Eligibility:

This is a non-therapeutic clinical trial that is open only to patients who were treated at St. Jude Children’s Research Hospital since 1980 and are currently followed at the hospital.

• St. Jude Children’s Research Hospital patient with acute leukemia (i.e., ALL or AML)
• Trisomy 21 Down syndrome diagnosis
• Completed all cancer therapy at St. Jude since 1980 and at least six months prior to study visit
• English as the primary language

Diseases Treated:

Non-therapeutic

Eligibility:

This is a non-therapeutic clinical trial that is open to St. Jude patients.

• Solid tumor or liquid tumor (cancerous or non-cancerous)

Diseases Treated:

• Acute lymphoblastic leukemia
• Acute myeloid leukemia
• Myelodysplasia
• Hodgkin lymphoma
• Non-Hodgkin lymphoma
• Juvenile myelomonocytic leukemia

Eligibility:

For transplant recipient:

• 21 years or younger
• Does not have a suitable sibling donor or volunteer unrelated donor
• Has a suitable single haplotype matched family member donor
• Diagnosed with high risk hematologic malignancy
• No prior allogeneic hematopoietic cell transplant

Diseases Treated:

Leukemia and lymphoma

Eligibility:

• 21 years and younger
• Does not have a suitable HLA-matched sibling donor or volunteer HLA-matched unrelated donor or is not a candidate for conventional matched donor transplant due to refractory disease
• Has a suitable single haplotype-matched family member donor
• High-risk hematologic malignancy, including certain diagnoses of:
  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia (AML)
  • Chronic myelogenous leukemia (CML)
  • Myelodysplastic syndrome (MDS)
  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

• Younger than 22 years old
• Diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) with minimal residual disease (MRD) between 0.1 and 4.99% after prior chemotherapy, relapse or stem cell transplant

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

Donor eligibility includes:

• At least 18 years old
• At least single haplotype matched family member
• HIV negative
• Not pregnant or breastfeeding

Recipient eligibility includes:

• 21 years old or younger*
• Diagnosed with relapsed and/or refractory CD19-positive leukemia
• Cohort A only – Relapsed and/or refractory CD19-positive leukemia AND previously received a hematopoietic cell transplant from the selected CAR-T donor
• Cohort B only: Can not receive autologous CD19-CAR T-cell therapy (per study)
• Detectable medullary leukemia

* Initial 3 participants must be at least 16 years old.

Diseases Treated:

Leukemia and other blood diseases

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

• Participant is receiving an allogeneic hematopoietic stem cell (HSC) transplant at St. Jude Children's Research Hospital using an unlicensed cord blood unit (CBU).
• Participant may be of any age and either gender.
• Participant has a medical disorder affecting the hematopoietic system that is inherited, acquired, or a result from myeloablative treatment.
• Participant is receiving HPC-CORD BLOOD product manufactured by NCBP (at least one, if the graft contains more than one units).

Diseases Treated:

ALL
AML
Carcinoma
Endocrine Tumors
Lymphoma
Melanoma
Neuroblastoma
Retinoblastoma
Ewing Sarcoma
Osteosarcoma
Rhabdomyosarcoma
Sarcomas

Eligibility:

This is a research study open only to St. Jude patients and their caregivers.

• 8 to 18 years old
• Within 16 weeks of initial cancer diagnosis
• Receiving outpatient chemotherapy treatment for cancer
• Can speak, read and write English. Parents who can speak, read, and write in English and Spanish
• Have Internet access

Diseases Treated:

Acute Lymphoblastic Leukemia and Lymphoma

Eligibility:

• Diagnosed with relapsed or refractory acute lymphoblastic leukemia or lymphoma
• Between 4 and 22 years old
• Weigh more than 20 kg (44.09 lbs.)
• Able to swallow pills
• No prior exposure to navitoclax
• Fully recovered from effects of any prior treatment

 

Diseases Treated:

• Leukemia
• Lymphoma
• Myeloid sarcoma
• Myelodysplastic syndrome

Eligibility:

• 21 years old and younger
• Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia
  • Myeloid sarcoma
  • Chronic myeloid leukemia (CML)
  • Juvenile myelomonocytic leukemia (JMML)
  • Myelodysplastic syndrome (MDS)
  • Non-Hodgkin lymphoma (NHL)
• Has a family member who is a suitable stem cell donor

Diseases Treated:

Acute myeloid leukemia

Eligibility:

• Diagnosis of one of the following:
  • Relapsed or refractory acute myeloid leukemia (AML)
  • Relapsed or refractory acute leukemia of ambiguous lineage (ALAL)
• 30 years old or younger (24 years or younger at St. Jude)
• Ineligible for other curative therapy

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

• Children and young adults up to 21 years old
• Refractory or relapsed CD19+ acute lymphoblastic leukemia (ALL)

 

 

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

Diseases Treated:

Childhood cancer incidence and survival

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

• Newly diagnosed with cancer between January 1, 1970, and December 31, 1996
• Survival five years from diagnosis
• Age less than 21 years at the time of diagnosis of cancer
• English or Spanish speaking and living in the United States or Canada at the time of diagnosis

Eligibility:

• Participants must be at least 5 years from diagnosis of childhood cancer between 1962-2012, treated and followed at St. Jude. 

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

• All patients being followed or treated at St. Jude Children’s Research Hospital for the diagnosis of childhood cancer
• Patient has not been permanently discharged from care and follow-up

Diseases Treated:

Hodgkin lymphoma

Eligibility:

Hodgkin lymphoma survivor

• Patient eligible for the St. Jude LIFE study
• Treated with thoracic radiation for Hodgkin lymphoma
• At least 18 years old
• At least 5 years from original diagnosis
• If participating remotely, must have Wi-Fi access

Comparison group

• Non-patient volunteer (Cannot be sibling, parent or child of the survivor participant)
• At least 18 years old
• Lives in the U.S.
• If participating remotely, must have Wi-Fi access

Diseases Treated:

Lymphoma

Eligibility:

• Previously untreated CD30+ classical Hodgkin lymphoma
• 21 years or younger at time of diagnosis (low-risk and intermediate-risk patients)
• 25 years or younger (high-risk patients)

Diseases Treated:

• Acute lymphoblastic leukemia
• Acute myeloid leukemia
• Myelodysplasia
• Hodgkin lymphoma
• Non-Hodgkin lymphoma
• Juvenile myelomonocytic leukemia

Eligibility:

• Ages 12–21 years
• Lymphoid or myeloid-based cancer that requires a bone marrow transplant

 

Diseases Treated:

Non-therapeutic

Eligibility:

This is a non-therapeutic clinical trial that is open to St. Jude patients.

• Solid tumor or liquid tumor (cancerous or non-cancerous)

Diseases Treated:

Leukemia and lymphoma

Eligibility:

• 21 years and younger
• Does not have a suitable HLA-matched sibling donor or volunteer HLA-matched unrelated donor or is not a candidate for conventional matched donor transplant due to refractory disease
• Has a suitable single haplotype-matched family member donor
• High-risk hematologic malignancy, including certain diagnoses of:
  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia (AML)
  • Chronic myelogenous leukemia (CML)
  • Myelodysplastic syndrome (MDS)
  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma

Diseases Treated:

Acute Lymphoblastic Leukemia and Lymphoma

Eligibility:

• Diagnosed with relapsed or refractory acute lymphoblastic leukemia or lymphoma
• Between 4 and 22 years old
• Weigh more than 20 kg (44.09 lbs.)
• Able to swallow pills
• No prior exposure to navitoclax
• Fully recovered from effects of any prior treatment

 

Diseases Treated:

• Leukemia
• Lymphoma
• Myeloid sarcoma
• Myelodysplastic syndrome

Eligibility:

• 21 years old and younger
• Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia
  • Myeloid sarcoma
  • Chronic myeloid leukemia (CML)
  • Juvenile myelomonocytic leukemia (JMML)
  • Myelodysplastic syndrome (MDS)
  • Non-Hodgkin lymphoma (NHL)
• Has a family member who is a suitable stem cell donor

Diseases Treated:

Spinal muscular atrophy

Eligibility:

• Genetic documentation of 5q spinal muscular atrophy (SMA)
• Ages 1 week to adult (age varies by study part)

Diseases Treated:

Duchenne muscular dystrophy

Eligibility:

• Male age 4 to 16 years old
• Diagnosed with Duchenne muscular dystrophy 

Diseases Treated:

Friedreich’s Ataxia

Eligibility:

• Patients with Friedreich’s Ataxia
• Birth to 22 years

Diseases Treated:

Neurological Disorders
Sickle Cell Disease
Hemophilia
Inherited Genetic Diseases

Eligibility:

• Non-therapeutic clinical trial
• Interviews conducted remotely
• 18-35-year-olds with rare genetic diseases
• Parents or caregivers of patients under 21 with rare genetic diseases
• Health care workers for gene therapy patients

Diseases Treated:

Charcot-Marie-Tooth Disease

Eligibility:

• Patients with Charcot-Marie-Tooth disease
• Birth to 22 years

Diseases Treated:

Spinal Muscular Atrophy Types 2 and 3

Eligibility:

• Between 2 and 21 years old
• Diagnosed with SMA type 2 or type 3 and not able to walk
• Those taking Spinraza must have taken it for at least 10 months.
• Those taking Evrsysdi must have taken it for at least 6 months.

Eligibility exclusions:

• Those who have previously received Zolgensma gene therapy

Diseases Treated:

Hodgkin lymphoma

Eligibility:

Hodgkin lymphoma survivor

• Patient eligible for the St. Jude LIFE study
• Treated with thoracic radiation for Hodgkin lymphoma
• At least 18 years old
• At least 5 years from original diagnosis
• If participating remotely, must have Wi-Fi access

Comparison group

• Non-patient volunteer (Cannot be sibling, parent or child of the survivor participant)
• At least 18 years old
• Lives in the U.S.
• If participating remotely, must have Wi-Fi access

Diseases Treated:

Craniopharyngioma

Eligibility:

• 21 years old or younger
• Diagnosis of craniopharyngioma

Diseases Treated:

Solid Tumors

Eligibility:

• Diagnosis of solid tumor that is resistant to other anticancer therapy or has come back after therapy. Includes lymphoma and central nervous system (CNS) tumors that may or may not require surgery.
• Fully recovered from the acute toxic effects of all prior anticancer therapy
• At least 1 but not more than 21 years of age
• Able to swallow tablets whole

Diseases Treated:

Hemophilia B

Eligibility:

• Male
• At least 18 years old
• Diagnosis of hemophilia B

Diseases Treated:

Neuroblastoma, pheochromocytoma

Eligibility:

This study is open to St. Jude patients only.

• Known or suspected neuroblastoma or pheochromocytoma
• At least 1 year old

 

Diseases Treated:

 Low-grade glioma

Eligibility:

• At least 6 years old and younger than 22
• Diagnosis of low-grade glioma

Diseases Treated:

Aplastic Anemia

Eligibility:

• 21 years old and younger
• Diagnosis of severe aplastic anemia
• No available matched donor

Diseases Treated:

Hemophagocytic Lymphohistiocytosis

Eligibility:

• 6 weeks to 22 years old
• Newly diagnosed hemophagocytic lymphohistiocytosis (HLH)
• Relapsed or refractory HLH

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

• Younger than 22 years old
• Diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) with minimal residual disease (MRD) between 0.1 and 4.99% after prior chemotherapy, relapse or stem cell transplant

Diseases Treated:

Solid tumors, Brain tumors

Eligibility:

• 6 months to 21 years old
• Solid tumor or brain tumor that has progressed or spread
• Failed standard treatment
• RET gene alteration

Diseases Treated:

Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma or high-grade glioma

Eligibility:

• Between 6 months and 18 years old with diagnosis of MSI-H solid tumor OR
• Between 12 years and 18 years old with diagnosis of melanoma OR
• Between 3 and 18 years old with relapsed or refractory classical Hodgkin lymphoma OR
• Between 12 and 18 years old with a diagnosis of Stage IIB, IIC, III, or IV melanoma, who had prior surgery to remove the tumor, but no other treatment (including radiation), no metastatic disease, and who have completely recovered. 
• Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
• Appropriate liver and kidney functions

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

Donor eligibility includes:

• At least 18 years old
• At least single haplotype matched family member
• HIV negative
• Not pregnant or breastfeeding

Recipient eligibility includes:

• 21 years old or younger*
• Diagnosed with relapsed and/or refractory CD19-positive leukemia
• Cohort A only – Relapsed and/or refractory CD19-positive leukemia AND previously received a hematopoietic cell transplant from the selected CAR-T donor
• Cohort B only: Can not receive autologous CD19-CAR T-cell therapy (per study)
• Detectable medullary leukemia

* Initial 3 participants must be at least 16 years old.

Diseases Treated:

Solid tumors
Ewing sarcoma

Eligibility:

• Ages 12 months old to 30 years
• Diagnosed with recurrent or refractory solid tumor (Phase 1)
• Diagnosed with recurrent or refractory Ewing sarcoma (Phase 2)

Diseases Treated:

Human Immunodeficiency Virus

Eligibility:

• At least 4 weeks old but younger than 18 years old
• Confirmed HIV-1 infection
• Current or past treatment with HIV medications (Children younger than 2 years old may be eligible even if they have not been treated with HIV medications.)

Diseases Treated:

Medulloblastoma

High-grade glioma (HGG)

Diffuse intrinsic pontine glioma (DIPG)

Eligibility:

• Recurrent, refractory or progressive medulloblastoma, high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG)
• Evidence of genetic activation of the MET pathway (expansion co-hort)
• At least 5 years old and 21 years old or younger

Diseases Treated:

Acute Myeloid Leukemia (AML)

Eligibility:

• Younger than 21 years of age
• Diagnosed with recurrent or refractory acute myeloid leukemia (AML)
• Weigh more than 17kg 
• Fully recovered from the acute toxic effects of all prior anti-cancer therapy

Diseases Treated:

Solid Tumor

Lymphoma

Brain Tumor

Eligibility:

• 12 months to 21 years old with diagnosis of:
  • Relapsed or refractory solid tumor or lymphoma (including CNS tumors) OR
  • Progressive or recurrent DIPG or other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy
• 12 months to 30 years old with diagnosis of relapsed or refractory osteosarcoma

Diseases Treated:

Sickle cell disease

Eligibility:

This is a non-therapeutic clinical trial that is open only to patients at St. Jude or Methodist Healthcare.

• Between 6 and 25 years old
• Diagnosed with sickle cell disease
• Seeking care for acute vaso-occlusive crisis pain at St. Jude Children’s Research Hospital or Methodist Healthcare
• Speaks English

Diseases Treated:

Diffuse Intrinsic Pontine Glioma, Glioma, CNS Tumor, Solid Tumor

Eligibility:

• Diagnosed with one of the following:
  • Recurrent or refractory solid tumor or central nervous system (CNS) tumor
  • Diffuse Intrinsic Pontine Glioma  (DIPG)
  • Newly diagnosed or recurrent high-grade glioma 
• Younger than 18 years old (Phase I) or between 3 and 25 years old (Efficacy Phase)

Diseases Treated:

• Leukemia
• Lymphoma
• Myeloid sarcoma
• Myelodysplastic syndrome

Eligibility:

• 21 years old and younger
• Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia
  • Myeloid sarcoma
  • Chronic myeloid leukemia (CML)
  • Juvenile myelomonocytic leukemia (JMML)
  • Myelodysplastic syndrome (MDS)
  • Non-Hodgkin lymphoma (NHL)
• Has a family member who is a suitable stem cell donor

Diseases Treated:

Craniopharyngioma

Eligibility:

• 21 years old or younger
• Diagnosis of craniopharyngioma

Diseases Treated:

Acute myeloid leukemia

Eligibility:

• Diagnosis of one of the following:
  • Relapsed or refractory acute myeloid leukemia (AML)
  • Relapsed or refractory acute leukemia of ambiguous lineage (ALAL)
• 30 years old or younger (24 years or younger at St. Jude)
• Ineligible for other curative therapy

Eligibility:

• Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
• Child has adequate blood, liver and kidney function.
• Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.

Diseases Treated:

Low-Grade Glioma

Eligibility:

At least 2 years old and younger than 25 years old

Diagnosis of progressive or relapsed low-grade glioma 

Diseases Treated:

Medulloblastoma (includes all variants of medulloblastoma and posterior fossa PNET)

Eligibility:

• Diagnosis of newly medulloblastoma
• At least 3 years old and younger than 22 years old (Strata W, S or N) OR
• At least 22 years old and younger than 40 years old AND has SHH medulloblastoma (Stratum S)
• Has not received previous treatment with radiation therapy or chemotherapy
• Must start treatment within 36 days of surgery to remove the tumor

Diseases Treated:

Non-therapeutic

Eligibility:

This is a non-therapeutic research study open only to St. Jude patients and their caregivers.

• 15 to 22 years old 
• Primary oncology diagnosis 
• Read and speak English 

Diseases Treated:

Non-therapeutic

Eligibility:

This is a non-therapeutic research study open only to St. Jude patients and their caregivers.

• 5 to 17 years old 
• Diagnosed with malignancy or CNS neoplasm
• Identified by the St. Jude Transition Oncology Program as a patient transitioning off active cancer therapy

Diseases Treated:

Hemophilia

Eligibility:

• St. Jude hemophilia patients
• 6–18 years old
• Speak English 

Diseases Treated:

Sickle Cell Disease

Eligibility:

This is a non-therapeutic study for patients at St. Jude Children’s Research Hospital and Methodist Adult Comprehensive Sickle Cell Center.

• Diagnosis of sickle cell disease (SCD)
• 16 to 20 years old
• English is primary language

Diseases Treated:

ALL
AML
Carcinoma
Endocrine Tumors
Lymphoma
Melanoma
Neuroblastoma
Retinoblastoma
Ewing Sarcoma
Osteosarcoma
Rhabdomyosarcoma
Sarcomas

Eligibility:

This is a research study open only to St. Jude patients and their caregivers.

• 8 to 18 years old
• Within 16 weeks of initial cancer diagnosis
• Receiving outpatient chemotherapy treatment for cancer
• Can speak, read and write English. Parents who can speak, read, and write in English and Spanish
• Have Internet access

Diseases Treated:

Craniopharyngioma

Eligibility:

• 21 years old or younger
• Diagnosis of craniopharyngioma

Diseases Treated:

Non-therapeutic

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

St. Jude Patients

• 8 to 17 years old 
• Sickle cell anemia 
• Enrolled on the Sickle Cell Clinical Research Intervention Program (SCCRIP) clinical trial 
• Completed Sickle Cell Assessment of Neuropsychology Skills (SCANS) assessment 
• Being treated with hydroxyurea (maximum tolerated dose) 
• Read and speak English

Siblings

• Siblings of St. Jude patients with sickle cell disease 
• Do not have sickle cell disease 
• 8 to 17 years old 

Diseases Treated:

Sickle Cell Disease

Eligibility:

• 25 years old or younger
• Diagnosed with severe sickle cell disease
• Has a suitable HLA-matched sibling donor or single haplotype matched (half matched) family member donor (parents or siblings)

Diseases Treated:

Non-therapeutic

Eligibility:

This is a non-therapeutic research study open only to St. Jude patients, their parents and patients' teachers.

• Patient between 4 and 6 years old
• Primary diagnosis of brain tumor or non-CNS solid tumor
• 6 to 12 months since therapy was completed (+/- 1 month) OR more than 18 months since therapy completion
• Chemotherapy was part of tumor treatment
• Able to speak and read English

Diseases Treated:

Medulloblastoma (includes all variants of medulloblastoma and posterior fossa PNET)

Eligibility:

• Diagnosis of newly medulloblastoma
• At least 3 years old and younger than 22 years old (Strata W, S or N) OR
• At least 22 years old and younger than 40 years old AND has SHH medulloblastoma (Stratum S)
• Has not received previous treatment with radiation therapy or chemotherapy
• Must start treatment within 36 days of surgery to remove the tumor

Diseases Treated:

Brain tumor

Eligibility:

This study is open only to patients at St. Jude Children’s Research Hospital.

• Diagnosis of medulloblastoma or other brain tumor
• Between 8 and 12 years old
• At least 2 years after completion of therapy
• Full-time student
• Speaks English

Diseases Treated:

Non-therapeutic

Eligibility:

This is a non-therapeutic research study open only to St. Jude patients and their caregivers.

• Caregiver is 18 years of age or older
• Caregiver is the patient’s biological parent, stepparent or primary legal guardian
• If more than 1 set of parents are involved in the patient’s care (e.g., 2 biologic and 2 stepparents or partners), the caregiver with legal decision-making responsibilities will be eligible for participation
• Caregiver is comfortable speaking and reading English

Diseases Treated:

Non-therapeutic

Eligibility:

This is a non-therapeutic research study open only to St. Jude patients and their caregivers.

• 5 to 17 years old 
• Diagnosed with malignancy or CNS neoplasm
• Identified by the St. Jude Transition Oncology Program as a patient transitioning off active cancer therapy

Diseases Treated:

ALL
AML
Carcinoma
Endocrine Tumors
Lymphoma
Melanoma
Neuroblastoma
Retinoblastoma
Ewing Sarcoma
Osteosarcoma
Rhabdomyosarcoma
Sarcomas

Eligibility:

This is a research study open only to St. Jude patients and their caregivers.

• 8 to 18 years old
• Within 16 weeks of initial cancer diagnosis
• Receiving outpatient chemotherapy treatment for cancer
• Can speak, read and write English. Parents who can speak, read, and write in English and Spanish
• Have Internet access

Diseases Treated:

Non-therapeutic

Eligibility:

Primary oncologist:

• Attending physician age 18 years or older who provides medical care to patients in the Solid Tumor or Neuro-Oncology Clinics at St. Jude Children’s Research Hospital
• Primary hematology-oncology fellows age 18 or older (audio-recorded disease reevaluation only)

Parents of children with cancer:

• Age 18 or older
• Biological parent, step-parent or primary legal guardian
• Reads and speaks English

Patients:

• Primary oncologist is enrolled in the study.
• 30 years old or younger
• Diagnosed with a solid tumor and/or a brain tumor

Diseases Treated:

Solid tumors

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

• Participant is under the care of a St. Jude physician with a known or suspected, newly diagnosed bone or soft tissue sarcoma who will be treated on or as per disease specific protocols and has not begun therapy OR participant has started therapy and the needed research imaging can be performed within 2-5 days of starting treatment. 
• Participant has undergone or is scheduled for PET-CT, Bone Scan, or PET-CT and Bone Scan within two (2) weeks of the whole body and primary tumor DWI-MRI. 
• Participant meets institutional MRI safety screening requirements. 
• Participant has not undergone primary tumor resection prior to arrival to St. Jude. 

Diseases Treated:

 Low-grade glioma

Eligibility:

• At least 6 years old and younger than 22
• Diagnosis of low-grade glioma

Diseases Treated:

Craniopharyngioma

Eligibility:

• 21 years old or younger
• Diagnosis of craniopharyngioma

Diseases Treated:

Non-therapeutic

Eligibility:

This is a non-therapeutic clinical trial open only to St. Jude patients.

• St. Jude patients receiving at least 5 daily fractions of proton therapy
• All patients receiving proton therapy at St. Jude will be screened for participation.

Diseases Treated:

Wilms Tumor

Eligibility:

• Diagnosis of Wilms tumor

Diseases Treated:

Sickle Cell Disease

Eligibility:

•  18 to 35 years old
• Diagnosed with severe sickle cell disease

Diseases Treated:

Sickle cell anemia, thalassemia

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

• At least 2 years old
• Diagnosed with sickle cell anemia or thalassemia
• No active disease, including painful crisis or active infection
• Adequate blood counts

Diseases Treated:

Sickle Cell Disease

Eligibility:

• 2–11 years old
• Diagnosed with severe sickle cell disease (SCD)

Diseases Treated:

Non-malignant blood diseases (non-therapeutic)

Eligibility:

• Receiving therapy or a consultation for a non-malignant blood disorder
• Biological relatives (with or without a non-malignant blood disorder) who agree to undergo genetic testing

Diseases Treated:

Sickle Cell Disease

Eligibility:

This is a non-therapeutic study for patients at St. Jude Children’s Research Hospital and Methodist Adult Comprehensive Sickle Cell Center.

• Diagnosis of sickle cell disease (SCD)
• 16 to 20 years old
• English is primary language

Diseases Treated:

Sickle cell disease

Eligibility:

This is a non-therapeutic clinical trial that is open only to patients at St. Jude or Methodist Healthcare.

• Between 6 and 25 years old
• Diagnosed with sickle cell disease
• Seeking care for acute vaso-occlusive crisis pain at St. Jude Children’s Research Hospital or Methodist Healthcare
• Speaks English

Diseases Treated:

Sickle cell disease

Eligibility:

• Participant has a diagnosis of Sickle Cell Disease of any genotype.

Diseases Treated:

Solid Tumors

Eligibility:

Inclusion criteria include:

• 21 years old or younger
• Relapsed or refractory B7-H3-positive solid tumor

Diseases Treated:

Solid Tumors

Eligibility:

• Diagnosis of solid tumor that is resistant to other anticancer therapy or has come back after therapy. Includes lymphoma and central nervous system (CNS) tumors that may or may not require surgery.
• Fully recovered from the acute toxic effects of all prior anticancer therapy
• At least 1 but not more than 21 years of age
• Able to swallow tablets whole

Diseases Treated:

Neuroblastoma

Eligibility:

• At least 1 year old
• Diagnosis of relapsed, refractory or progressive neuroblastoma

Diseases Treated:

Solid tumors
Hepatocellular carcinoma
Fibrolamellar hepatocellular carcinoma
Sarcomas
Malignant rhabdoid tumors
Desmoplastic small round cell tumors

Eligibility:

Part 1

• 1–30 years old
• Diagnosis of a solid tumor that has grown or has come back after treatment
• Tumor accessible through biopsy

Part 2

• 1–30 years old
• Diagnosis of:
  • Hepatocellular carcinoma that has grown or has come back after treatment
  • Fibrolamellar hepatocellular carcinoma
  • Desmoplastic small round cell tumor
  • Malignant rhabdoid tumor that is not in the central nervous system
• Tumor accessible through biopsy

Diseases Treated:

Osteosarcoma

Eligibility:

Less than 40 years old

A new diagnosis of high-grade osteosarcoma

Must be able to swallow tablets

The current phase is only open to patients with metastatic disease

Diseases Treated:

Solid tumors

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

• Participant is under the care of a St. Jude physician with a known or suspected, newly diagnosed bone or soft tissue sarcoma who will be treated on or as per disease specific protocols and has not begun therapy OR participant has started therapy and the needed research imaging can be performed within 2-5 days of starting treatment. 
• Participant has undergone or is scheduled for PET-CT, Bone Scan, or PET-CT and Bone Scan within two (2) weeks of the whole body and primary tumor DWI-MRI. 
• Participant meets institutional MRI safety screening requirements. 
• Participant has not undergone primary tumor resection prior to arrival to St. Jude. 

Diseases Treated:

Neuroblastoma, pheochromocytoma

Eligibility:

This study is open to St. Jude patients only.

• Known or suspected neuroblastoma or pheochromocytoma
• At least 1 year old

 

Diseases Treated:

Non-therapeutic

Eligibility:

This is a non-therapeutic clinical trial that is open to St. Jude patients.

• Solid tumor or liquid tumor (cancerous or non-cancerous)

Diseases Treated:

Adrenocortical tumors (carcinoma and adenoma)

Eligibility:

• Diagnosis of an adrenocortical tumor (ACT)
• 21 years of age or younger at diagnosis
• Relatives of patients with ACT

Diseases Treated:

Solid tumors, Brain tumors

Eligibility:

• 6 months to 21 years old
• Solid tumor or brain tumor that has progressed or spread
• Failed standard treatment
• RET gene alteration

Diseases Treated:

Melanoma

Eligibility:

• Diagnosed with a melanoma tumor that is malignant (cancerous) or that might be cancerous, including:
  • Conventional or “adult-type” melanoma
  • Spitzoid melanoma/atypical Spitz tumor
  • Congenital melanoma
  • Melanoma arising in a giant congenital nevus
  • Melanocytic lesions with indeterminate biological behavior (e.g., pigment-synthesizing melanomas)
• Younger than 19 years of age 

Diseases Treated:

Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma or high-grade glioma

Eligibility:

• Between 6 months and 18 years old with diagnosis of MSI-H solid tumor OR
• Between 12 years and 18 years old with diagnosis of melanoma OR
• Between 3 and 18 years old with relapsed or refractory classical Hodgkin lymphoma OR
• Between 12 and 18 years old with a diagnosis of Stage IIB, IIC, III, or IV melanoma, who had prior surgery to remove the tumor, but no other treatment (including radiation), no metastatic disease, and who have completely recovered. 
• Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
• Appropriate liver and kidney functions

Diseases Treated:

Neuroblastoma, ganglioneuroblastoma

Eligibility:

• Participant has been enrolled on ANBLB1 (ANBL00B1).
• Participant has newly diagnosed MYCN non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma.
• Participant is less than 12 months (Group A) and less than 18 months (Group B and Group C) of age at diagnosis.

 

Diseases Treated:

Solid tumors
Ewing sarcoma

Eligibility:

• Ages 12 months old to 30 years
• Diagnosed with recurrent or refractory solid tumor (Phase 1)
• Diagnosed with recurrent or refractory Ewing sarcoma (Phase 2)

Diseases Treated:

ALL
AML
Carcinoma
Endocrine Tumors
Lymphoma
Melanoma
Neuroblastoma
Retinoblastoma
Ewing Sarcoma
Osteosarcoma
Rhabdomyosarcoma
Sarcomas

Eligibility:

This is a research study open only to St. Jude patients and their caregivers.

• 8 to 18 years old
• Within 16 weeks of initial cancer diagnosis
• Receiving outpatient chemotherapy treatment for cancer
• Can speak, read and write English. Parents who can speak, read, and write in English and Spanish
• Have Internet access

Diseases Treated:

Recurrent, progressive, or refractory high-grade gliomas

Eligibility:

• Participant has recurrent, progressive or refractory non-brainstem high-grade glioma or diffuse intrinsic pontine glioma (DIPG)
• Participant is 1 to 18 years of age
• Participant has bi-measurable disease on MRI 
• Participant has received prior radiation therapy and/or chemotherapy and has not received myelosuppressive anticancer chemotherapy for at least three (3) weeks

 

Diseases Treated:

Solid Tumor

Lymphoma

Brain Tumor

Eligibility:

• 12 months to 21 years old with diagnosis of:
  • Relapsed or refractory solid tumor or lymphoma (including CNS tumors) OR
  • Progressive or recurrent DIPG or other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy
• 12 months to 30 years old with diagnosis of relapsed or refractory osteosarcoma

Diseases Treated:

Diffuse Intrinsic Pontine Glioma, Glioma, CNS Tumor, Solid Tumor

Eligibility:

• Diagnosed with one of the following:
  • Recurrent or refractory solid tumor or central nervous system (CNS) tumor
  • Diffuse Intrinsic Pontine Glioma  (DIPG)
  • Newly diagnosed or recurrent high-grade glioma 
• Younger than 18 years old (Phase I) or between 3 and 25 years old (Efficacy Phase)

Diseases Treated:

Retinoblastoma

Eligibility:

This study is currently open only to patients at St. Jude Children's Research Hospital.

• 7 years old or younger
• Part I
  • Diagnosed with retinoblastoma and has not received any treatment OR
  • Diagnosed with cataracts and has not received any treatment OR
  • Diagnosed with glaucoma and has not received any treatment
• Part II
  • Referred to an eye doctor to check for leukocoria or other eye conditions
• Part III
  • Diagnosed with retinoblastoma and is receiving treatment

Diseases Treated:

Wilms Tumor

Eligibility:

• Diagnosis of Wilms tumor

Diseases Treated:

Non-therapeutic

Eligibility:

Primary oncologist:

• Attending physician age 18 years or older who provides medical care to patients in the Solid Tumor or Neuro-Oncology Clinics at St. Jude Children’s Research Hospital
• Primary hematology-oncology fellows age 18 or older (audio-recorded disease reevaluation only)

Parents of children with cancer:

• Age 18 or older
• Biological parent, step-parent or primary legal guardian
• Reads and speaks English

Patients:

• Primary oncologist is enrolled in the study.
• 30 years old or younger
• Diagnosed with a solid tumor and/or a brain tumor

Diseases Treated:

Adrenocortical tumors (carcinoma and adenoma)

Eligibility:

• Diagnosis of an adrenocortical tumor (ACT)
• 21 years of age or younger at diagnosis
• Relatives of patients with ACT

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

Eligibility:

• Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
• Child has adequate blood, liver and kidney function.
• Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.